Yongquan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yongquan Chen has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Bin Wang
Department of Anesthesiology, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu, China
5 shared publications Wei Chen
Department of Anaesthesiology, Yijishan Hospital, the First Affiliated Hospital of Wannan Medical University, No.2 Zheshan West Road, WuHu, 241000, China
5 shared publications- Weidong Yao
Department of Anesthesiology, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu, China
4 shared publications - Yu-Long Wang
Department of Anesthesiology, the First Affiliated Hospital of Wannan Medical College, Wuhu, China
4 shared publications Bin Wang
Department of Anaesthesiology, Yijishan Hospital, the First Affiliated Hospital of Wannan Medical University, No.2 Zheshan West Road, WuHu, 241000, China
3 shared publicationsShangping Fang
Wannan Medical University, Wuhu, China
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in BMC Anesthesiology
Application research of POCUS based on wireless mixed reality ultrasound imaging technology in pediatric arterial catheterization
- 26 October 2026
- Published by Springer Nature in BMC Anesthesiology
Open AccessApplication research of POCUS based on wireless mixed reality ultrasound imaging technology in pediatric arterial catheterization
- Open Access
- 26 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Network pharmacology, molecular docking, molecular dynamics and animal experimental validation to investigate the mechanism of hydrocortisone in treating sepsis-induced acute lung injury
Sepsis-induced acute lung injury (SALI) is a critical condition associated with high morbidity and mortality in the intensive care unit. It is often triggered by severe infection, leading to an excessive and dysregulated inflammatory response, disruption of the alveolar-capillary barrier, and progressive respiratory failure. Although hydrocortisone (HC), as a classic glucocorticoid, is widely used in clinical anti-inflammatory therapy, its specific molecular mechanisms in sepsis-induced ALI remain incompletely elucidated. Network pharmacology was employed to identify potential targets and pathways of HC in the treatment of SALI. Molecular docking and molecular dynamics (MD) simulations were used to validate the interactions between HC and core targets. Subsequently, a cecal ligation and puncture (CLP)-induced SALI animal model was established to further verify the most critical targets. Network pharmacology analysis comprehensively identified 170 key targets related to HC treatment in SALI. Gene Ontology (GO) enrichment analysis revealed essential biological processes (BP), cellular components (CC), and molecular functions (MF), including cytokine signaling pathways, response to lipopolysaccharide, regulation of cytokine production, intracellular substance transport, and cellular signaling. KEGG enrichment analysis indicated that lipid metabolism, immune response, inflammatory diseases, and signaling pathways such as PI3K-Akt and HIF-1 play significant roles in SALI. Protein-protein interaction (PPI) network analysis identified eight core targets: RELA, MAPK3, HSP90AA1, TLR2, HIF-1 A, MAPK1, BCL2, and MYC. Molecular docking demonstrated potential binding mechanisms and affinity between HC and these key targets, indicating strong binding potential. MD simulations, including root mean square deviation (RMSD) and radius of gyration (Rg) analyses, further confirmed the stable binding of HC to these targets. Animal experiments additionally validated the significance of the NF-κB/HIF-1α signaling pathway in HC-treated SALI. This study adopted a multifaceted approach to explore the role and mechanisms of HC in SALI, providing a new theoretical foundation for the treatment of SALI.
- 26 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessNetwork pharmacology, molecular docking, molecular dynamics and animal experimental validation to investigate the mechanism of hydrocortisone in treating sepsis-induced acute lung injury
Sepsis-induced acute lung injury (SALI) is a critical condition associated with high morbidity and mortality in the intensive care unit. It is often triggered by severe infection, leading to an excessive and dysregulated inflammatory response, disruption of the alveolar-capillary barrier, and progressive respiratory failure. Although hydrocortisone (HC), as a classic glucocorticoid, is widely used in clinical anti-inflammatory therapy, its specific molecular mechanisms in sepsis-induced ALI remain incompletely elucidated. Network pharmacology was employed to identify potential targets and pathways of HC in the treatment of SALI. Molecular docking and molecular dynamics (MD) simulations were used to validate the interactions between HC and core targets. Subsequently, a cecal ligation and puncture (CLP)-induced SALI animal model was established to further verify the most critical targets. Network pharmacology analysis comprehensively identified 170 key targets related to HC treatment in SALI. Gene Ontology (GO) enrichment analysis revealed essential biological processes (BP), cellular components (CC), and molecular functions (MF), including cytokine signaling pathways, response to lipopolysaccharide, regulation of cytokine production, intracellular substance transport, and cellular signaling. KEGG enrichment analysis indicated that lipid metabolism, immune response, inflammatory diseases, and signaling pathways such as PI3K-Akt and HIF-1 play significant roles in SALI. Protein-protein interaction (PPI) network analysis identified eight core targets: RELA, MAPK3, HSP90AA1, TLR2, HIF-1 A, MAPK1, BCL2, and MYC. Molecular docking demonstrated potential binding mechanisms and affinity between HC and these key targets, indicating strong binding potential. MD simulations, including root mean square deviation (RMSD) and radius of gyration (Rg) analyses, further confirmed the stable binding of HC to these targets. Animal experiments additionally validated the significance of the NF-κB/HIF-1α signaling pathway in HC-treated SALI. This study adopted a multifaceted approach to explore the role and mechanisms of HC in SALI, providing a new theoretical foundation for the treatment of SALI.
- Open Access
- 22 June 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Norepinephrine versus colloid for preventing spinal anesthesia-induced hypotension and its impact on intracranial pressure in preeclamptic parturients: a randomized double-blind controlled trial
This study aims to evaluate the effects of two strategies for preventing hypotension after spinal anesthesia (prophylactic fluid loading and norepinephrine infusion) on intracranial pressure (ICP) in preeclamptic women by measuring the optic nerve sheath diameter (ONSD) using ultrasound. In this prospective, randomized, controlled trial, 60 healthy parturients and 60 preeclamptic parturients undergoing cesarean delivery under spinal anesthesia were enrolled. Normal parturients were randomly assigned to the infusion group (NA group, n = 30) and NE (norepinephrine) group (NB group, n = 30), while preeclamptic parturients were randomly assigned to the infusion group (PA group, n = 30) and NE group (PB group, n = 30). The primary outcome was bilateral ONSD values at baseline, pretreatment, 5 min after spinal anesthesia (Post-SA), and 5 min after fetal delivery (Post-birth). The secondary outcomes included maternal general characteristics, renal function indices, postoperative headache, fetal umbilical cord arterial blood gas indices, and Apgar scores. Pretreatment ONSD was significantly higher than baseline in both infusion groups, and baseline ONSD was higher in preeclamptic versus normal parturients (all P < 0.01). Among preeclamptic parturients, pretreatment ONSD was higher in the PA group than in the PB group (P < 0.01), with a similar difference (PA > PB) confirmed in normal parturients (P < 0.01). In addition, compared to the PA group, the PB group showed no significant differences in systolic blood pressure (SBP), diastolic blood pressure (DBP), or mean arterial pressure (MAP) at any time point in preeclamptic parturients (P > 0.05). Conversely, in normal parturients, post-birth SBP, DBP, and MAP were significantly higher in the NB than in the NA group (P < 0.01). Baseline hemodynamic values were higher in preeclamptic versus normal parturients (P < 0.01), and post-birth values decreased significantly from baseline in the PA and PB groups (P < 0.001). No significant intergroup differences were observed in maternal heart rate (HR), renal function indices, umbilical artery blood gas indices, Apgar scores, or the incidence of postpartum headache (all P > 0.05). For preeclamptic parturients, the risks induced by ICP increase should be noted. Compared to colloids, prophylactic infusion of NE was more effective and safer and did not increase ICP. This randomized controlled trial was registered on Chinese Clinical Trial Registry (ChiCTR2400092317; http://www.chictr.org.cn/) with the Clinical Trial Registry ({1}).- 22 June 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessNorepinephrine versus colloid for preventing spinal anesthesia-induced hypotension and its impact on intracranial pressure in preeclamptic parturients: a randomized double-blind controlled trial
This study aims to evaluate the effects of two strategies for preventing hypotension after spinal anesthesia (prophylactic fluid loading and norepinephrine infusion) on intracranial pressure (ICP) in preeclamptic women by measuring the optic nerve sheath diameter (ONSD) using ultrasound. In this prospective, randomized, controlled trial, 60 healthy parturients and 60 preeclamptic parturients undergoing cesarean delivery under spinal anesthesia were enrolled. Normal parturients were randomly assigned to the infusion group (NA group, n = 30) and NE (norepinephrine) group (NB group, n = 30), while preeclamptic parturients were randomly assigned to the infusion group (PA group, n = 30) and NE group (PB group, n = 30). The primary outcome was bilateral ONSD values at baseline, pretreatment, 5 min after spinal anesthesia (Post-SA), and 5 min after fetal delivery (Post-birth). The secondary outcomes included maternal general characteristics, renal function indices, postoperative headache, fetal umbilical cord arterial blood gas indices, and Apgar scores. Pretreatment ONSD was significantly higher than baseline in both infusion groups, and baseline ONSD was higher in preeclamptic versus normal parturients (all P < 0.01). Among preeclamptic parturients, pretreatment ONSD was higher in the PA group than in the PB group (P < 0.01), with a similar difference (PA > PB) confirmed in normal parturients (P < 0.01). In addition, compared to the PA group, the PB group showed no significant differences in systolic blood pressure (SBP), diastolic blood pressure (DBP), or mean arterial pressure (MAP) at any time point in preeclamptic parturients (P > 0.05). Conversely, in normal parturients, post-birth SBP, DBP, and MAP were significantly higher in the NB than in the NA group (P < 0.01). Baseline hemodynamic values were higher in preeclamptic versus normal parturients (P < 0.01), and post-birth values decreased significantly from baseline in the PA and PB groups (P < 0.001). No significant intergroup differences were observed in maternal heart rate (HR), renal function indices, umbilical artery blood gas indices, Apgar scores, or the incidence of postpartum headache (all P > 0.05). For preeclamptic parturients, the risks induced by ICP increase should be noted. Compared to colloids, prophylactic infusion of NE was more effective and safer and did not increase ICP. This randomized controlled trial was registered on Chinese Clinical Trial Registry (ChiCTR2400092317; http://www.chictr.org.cn/) with the Clinical Trial Registry ({1}). - 21 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 17255-17276
Integrating network pharmacology, molecular docking, machine learning, and experimental validation: puerarin improves sepsis-induced acute kidney injury via the Sirt1-Nrf2-HO-1 pathway
Acute kidney injury (AKI) associated with sepsis has a high clinical mortality rate, and there is a lack of effective therapeutic targets; uncontrolled oxidative stress and inflammatory responses are central pathological mechanisms. The Sirt1-Nrf2-HO-1 pathway plays a key role in renal antioxidant and anti-inflammatory protection. Although puerarin possesses anti-inflammatory and antioxidant activity, its specific molecular mechanisms for improving sepsis-induced AKI have not yet been fully elucidated. The aim of this study was to determine whether puerarin protects against sepsis-induced AKI by activating the Sirt1-Nrf2-HO-1 pathway and to establish a theoretical foundation for its clinical application. Using network pharmacology, we identified Sirt1, Nrf2, and HO-1 as key targets linked to oxidative stress and inflammation. Molecular docking suggested that puerarin binds well to all three proteins. In both cell and animal studies, we found that puerarin activates the Sirt1-Nrf2-HO-1 pathway, which in turn improves kidney function, reduces tissue damage, and lowers oxidative stress and inflammation. Our findings suggest that puerarin protects against sepsis-induced AKI by triggering the Sirt1-Nrf2-HO-1 pathway, pointing to this signaling axis as a possible target for treatment.
- 21 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 17255-17276
Integrating network pharmacology, molecular docking, machine learning, and experimental validation: puerarin improves sepsis-induced acute kidney injury via the Sirt1-Nrf2-HO-1 pathway
Acute kidney injury (AKI) associated with sepsis has a high clinical mortality rate, and there is a lack of effective therapeutic targets; uncontrolled oxidative stress and inflammatory responses are central pathological mechanisms. The Sirt1-Nrf2-HO-1 pathway plays a key role in renal antioxidant and anti-inflammatory protection. Although puerarin possesses anti-inflammatory and antioxidant activity, its specific molecular mechanisms for improving sepsis-induced AKI have not yet been fully elucidated. The aim of this study was to determine whether puerarin protects against sepsis-induced AKI by activating the Sirt1-Nrf2-HO-1 pathway and to establish a theoretical foundation for its clinical application. Using network pharmacology, we identified Sirt1, Nrf2, and HO-1 as key targets linked to oxidative stress and inflammation. Molecular docking suggested that puerarin binds well to all three proteins. In both cell and animal studies, we found that puerarin activates the Sirt1-Nrf2-HO-1 pathway, which in turn improves kidney function, reduces tissue damage, and lowers oxidative stress and inflammation. Our findings suggest that puerarin protects against sepsis-induced AKI by triggering the Sirt1-Nrf2-HO-1 pathway, pointing to this signaling axis as a possible target for treatment.
- Open Access
- 20 May 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Effect of dexamethasone on perioperative blood glucose in diabetic patients undergoing thoracoscopic surgery: a randomized, double-blind controlled trial
- 20 May 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessEffect of dexamethasone on perioperative blood glucose in diabetic patients undergoing thoracoscopic surgery: a randomized, double-blind controlled trial
- 6 May 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (6) , 1855-1869
C1q-mediated synapse loss by microglial phagocytosis is associated with postoperative neurocognitive disorder in mice
- 6 May 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (6) , 1855-1869
C1q-mediated synapse loss by microglial phagocytosis is associated with postoperative neurocognitive disorder in mice
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-17
Cuproptosis in Sepsis: Cell Type-Specific Mechanisms and Clinical Prospects
Sepsis is a life-threatening clinical syndrome caused by a severely dysregulated host response to infection. As a major global health challenge, it continues to exhibit high mortality. Copper, an essential trace element crucial for biological homeostasis, is central to a recently defined form of cell death: cuprotosis. This novel, copper-dependent mitochondrial cell death pathway is mechanistically distinct from classical apoptosis and pyroptosis. In sepsis, cuprotosis contributes significantly to immune dysfunction and organ failure by mediating the death of both immune cells (e.g. macrophages, lymphocytes) and parenchymal cells (e.g. cardiomyocytes, renal tubular cells). Therefore, modulating this regulatory mechanism in a cell type–specific manner may represent a novel potential therapeutic avenue for sepsis, although substantial clinical validation is still required. This review systematically outlines the core mechanisms of cuprotosis, elucidates its pathophysiological role in sepsis, and evaluates the potential and challenges of targeting cuprotosis for sepsis therapy.
- 1 April 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-17
Open AccessCuproptosis in Sepsis: Cell Type-Specific Mechanisms and Clinical Prospects
Sepsis is a life-threatening clinical syndrome caused by a severely dysregulated host response to infection. As a major global health challenge, it continues to exhibit high mortality. Copper, an essential trace element crucial for biological homeostasis, is central to a recently defined form of cell death: cuprotosis. This novel, copper-dependent mitochondrial cell death pathway is mechanistically distinct from classical apoptosis and pyroptosis. In sepsis, cuprotosis contributes significantly to immune dysfunction and organ failure by mediating the death of both immune cells (e.g. macrophages, lymphocytes) and parenchymal cells (e.g. cardiomyocytes, renal tubular cells). Therefore, modulating this regulatory mechanism in a cell type–specific manner may represent a novel potential therapeutic avenue for sepsis, although substantial clinical validation is still required. This review systematically outlines the core mechanisms of cuprotosis, elucidates its pathophysiological role in sepsis, and evaluates the potential and challenges of targeting cuprotosis for sepsis therapy.
- Open Access
- 31 March 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (4) , e70852
Activation of GPR35 in the Anterior Cingulate Cortex Alleviates Neuropathic Pain and Depression‐Related Behavior
Background: Neuropathic pain (NP) is frequently accompanied by anxiety and depression, and current treatments do not adequately address this comorbidity. The anterior cingulate cortex (ACC) plays a central role in sensory and emotional processing. However, the molecular pathways that connect these functions remain unclear. G protein‐coupled receptor 35 (GPR35), an orphan receptor enriched in neurons, has been implicated in neuroinflammation and pain signaling. However, its specific involvement in NP and associated affective disturbances has not been fully elucidated. Methods: Peripheral blood GPR35 expression was measured in human patients with NP and healthy controls. In mice, chronic constriction injury (CCI) was used to induce NP. Lentiviral knockdown or overexpression of GPR35 was performed in ACC cells. Behavioral assays were used to assess mechanical and thermal sensitivity, locomotor and anxiety metrics, cognitive performance, and depression‐related behaviors. Molecular analyses included western blotting, RT‐qPCR, immunofluorescence, RNA sequencing, and co‐immunoprecipitation. Additional Nr4a1 knockdown and L‐kynurenine (L‐Kyna, a GPR35 agonist) administration were used to validate pathway involvement. Results: Patients with NP had higher circulating GPR35 levels, which positively correlated with pain intensity. CCI induced a time‐dependent increase in GPR35 expression in the ACC of mice, accompanied by hypersensitivity and emotional disturbances. GPR35 knockdown in the ACC worsens mechanical and thermal hypersensitivity, impairs cognition, increases depression‐related behaviors, and amplifies microglial activation and pro‐inflammatory cytokine production. GPR35 overexpression reversed these effects by reducing hypersensitivity, improving affective behaviors, and restoring the inflammatory balance. Transcriptomic and biochemical analyses identified Nr4a1 as a key downstream effector of GPR35, and Nr4a1 knockdown eliminated the protective effects of GPR35 overexpression. GPR35 primarily regulated the PI3K/AKT pathway. Treatment with L‐Kyna reduced pain hypersensitivity, improved depression‐related behaviors, and decreased neuroinflammation in CCI mice. Conclusions: GPR35 is an essential regulator of NP and pain‐related affective disturbances in the ACC. Its effects are mediated through the Nr4a1‐dependent activation of the PI3K/AKT pathway and suppression of neuroinflammation. The pharmacological activation of GPR35 using L‐Kyna provides analgesic and antidepressant benefits, highlighting GPR35 as a promising therapeutic target for NP and its emotional comorbidities.
- 31 March 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (4) , e70852
Open AccessActivation of GPR35 in the Anterior Cingulate Cortex Alleviates Neuropathic Pain and Depression‐Related Behavior
Background: Neuropathic pain (NP) is frequently accompanied by anxiety and depression, and current treatments do not adequately address this comorbidity. The anterior cingulate cortex (ACC) plays a central role in sensory and emotional processing. However, the molecular pathways that connect these functions remain unclear. G protein‐coupled receptor 35 (GPR35), an orphan receptor enriched in neurons, has been implicated in neuroinflammation and pain signaling. However, its specific involvement in NP and associated affective disturbances has not been fully elucidated. Methods: Peripheral blood GPR35 expression was measured in human patients with NP and healthy controls. In mice, chronic constriction injury (CCI) was used to induce NP. Lentiviral knockdown or overexpression of GPR35 was performed in ACC cells. Behavioral assays were used to assess mechanical and thermal sensitivity, locomotor and anxiety metrics, cognitive performance, and depression‐related behaviors. Molecular analyses included western blotting, RT‐qPCR, immunofluorescence, RNA sequencing, and co‐immunoprecipitation. Additional Nr4a1 knockdown and L‐kynurenine (L‐Kyna, a GPR35 agonist) administration were used to validate pathway involvement. Results: Patients with NP had higher circulating GPR35 levels, which positively correlated with pain intensity. CCI induced a time‐dependent increase in GPR35 expression in the ACC of mice, accompanied by hypersensitivity and emotional disturbances. GPR35 knockdown in the ACC worsens mechanical and thermal hypersensitivity, impairs cognition, increases depression‐related behaviors, and amplifies microglial activation and pro‐inflammatory cytokine production. GPR35 overexpression reversed these effects by reducing hypersensitivity, improving affective behaviors, and restoring the inflammatory balance. Transcriptomic and biochemical analyses identified Nr4a1 as a key downstream effector of GPR35, and Nr4a1 knockdown eliminated the protective effects of GPR35 overexpression. GPR35 primarily regulated the PI3K/AKT pathway. Treatment with L‐Kyna reduced pain hypersensitivity, improved depression‐related behaviors, and decreased neuroinflammation in CCI mice. Conclusions: GPR35 is an essential regulator of NP and pain‐related affective disturbances in the ACC. Its effects are mediated through the Nr4a1‐dependent activation of the PI3K/AKT pathway and suppression of neuroinflammation. The pharmacological activation of GPR35 using L‐Kyna provides analgesic and antidepressant benefits, highlighting GPR35 as a promising therapeutic target for NP and its emotional comorbidities.
- Open Access
- 12 February 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Fluid responsiveness-guided individualized strategy for preventing hypotension after spinal anesthesia in cesarean delivery: a randomized trial of prehydration versus norepinephrine preinfusion
Objective: This study aimed to evaluate the efficacy of fluid responsiveness-guided strategies for preventing spinal anesthesia-induced hypotension (SAIH) in parturients undergoing cesarean delivery, comparing prophylactic fluid loading with norepinephrine infusion. Methods: In this fluid responsiveness-based stratified randomized controlled trial, eligible parturients were stratified into fluid responsive (FR(+)) and non-fluid responsive (FR(-)) cohorts according to carotid corrected flow time (FTc). Each stratum had a preset sample size of 236, and within each stratum, participants were randomly assigned to receive either prophylactic colloid infusion (Co) or norepinephrine infusion (NE), ultimately forming four subgroups: FR(+)/Co, FR(+)/NE, FR(-)/Co, and FR(-)/NE.Primary outcomes included the incidence of SAIH and maximum reduction in mean arterial pressure (MAP). Secondary outcomes encompassed neonatal umbilical cord blood gas analysis, Apgar scores, intraoperative hemodynamic changes, and postoperative recovery parameters. Results: Among fluid-responsive parturients, prophylactic fluid loading (FR(+)/Co) and norepinephrine infusion (FR(+)/NE) demonstrated comparable efficacy in preventing SAIH (16.7% vs. 15.1%, P > 0.05). In contrast, non-fluid-responsive parturients receiving fluid loading (FR(-)/Co) had a significantly higher SAIH incidence (34.2%) compared to those receiving norepinephrine (FR(-)/NE, 13.6%, P = 0.0004). Neonatal umbilical cord blood lactate levels were higher in the FR(+)/NE group compared to the FR(+)/Co group (1.66 ± 0.25 mmol/L vs. 1.55 ± 0.28 mmol/L, P = 0.006), suggesting potential fetal hypoxia. Additionally, the FR(+)/NE group exhibited prolonged postoperative gastrointestinal recovery times compared to the FR(+)/Co group (29 [20, 39] h vs. 24 [16, 35] h, P = 0.0438). Conclusion: Fluid loading is optimal for fluid-responsive parturients, whereas norepinephrine infusion is superior for non-fluid-responsive parturients. These findings advocate for fluid responsiveness-guided individualized SAIH prevention strategies to optimize maternal and neonatal outcomes. Trial registration: This trial was prospectively registered at ClinicalTrials.gov (ChiCTR2400084392) on May 15, 2024, prior to participant enrollment.
- 12 February 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessFluid responsiveness-guided individualized strategy for preventing hypotension after spinal anesthesia in cesarean delivery: a randomized trial of prehydration versus norepinephrine preinfusion
Objective: This study aimed to evaluate the efficacy of fluid responsiveness-guided strategies for preventing spinal anesthesia-induced hypotension (SAIH) in parturients undergoing cesarean delivery, comparing prophylactic fluid loading with norepinephrine infusion. Methods: In this fluid responsiveness-based stratified randomized controlled trial, eligible parturients were stratified into fluid responsive (FR(+)) and non-fluid responsive (FR(-)) cohorts according to carotid corrected flow time (FTc). Each stratum had a preset sample size of 236, and within each stratum, participants were randomly assigned to receive either prophylactic colloid infusion (Co) or norepinephrine infusion (NE), ultimately forming four subgroups: FR(+)/Co, FR(+)/NE, FR(-)/Co, and FR(-)/NE.Primary outcomes included the incidence of SAIH and maximum reduction in mean arterial pressure (MAP). Secondary outcomes encompassed neonatal umbilical cord blood gas analysis, Apgar scores, intraoperative hemodynamic changes, and postoperative recovery parameters. Results: Among fluid-responsive parturients, prophylactic fluid loading (FR(+)/Co) and norepinephrine infusion (FR(+)/NE) demonstrated comparable efficacy in preventing SAIH (16.7% vs. 15.1%, P > 0.05). In contrast, non-fluid-responsive parturients receiving fluid loading (FR(-)/Co) had a significantly higher SAIH incidence (34.2%) compared to those receiving norepinephrine (FR(-)/NE, 13.6%, P = 0.0004). Neonatal umbilical cord blood lactate levels were higher in the FR(+)/NE group compared to the FR(+)/Co group (1.66 ± 0.25 mmol/L vs. 1.55 ± 0.28 mmol/L, P = 0.006), suggesting potential fetal hypoxia. Additionally, the FR(+)/NE group exhibited prolonged postoperative gastrointestinal recovery times compared to the FR(+)/Co group (29 [20, 39] h vs. 24 [16, 35] h, P = 0.0438). Conclusion: Fluid loading is optimal for fluid-responsive parturients, whereas norepinephrine infusion is superior for non-fluid-responsive parturients. These findings advocate for fluid responsiveness-guided individualized SAIH prevention strategies to optimize maternal and neonatal outcomes. Trial registration: This trial was prospectively registered at ClinicalTrials.gov (ChiCTR2400084392) on May 15, 2024, prior to participant enrollment.
- Open Access
- 10 February 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
GPR35 protects against reperfusion injury in ischemic stroke by binding with the CR2 domain of Raf1
Ischemic stroke remains a leading cause of global mortality and disability. While timely vascular recanalization is the most direct and clinically validate
- 10 February 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessGPR35 protects against reperfusion injury in ischemic stroke by binding with the CR2 domain of Raf1
Ischemic stroke remains a leading cause of global mortality and disability. While timely vascular recanalization is the most direct and clinically validate